HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5-imino-13-deoxydoxorubicin

has antineoplastic activity; structure in first source

Also Known As:

GPX-150

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Olson, Richard D: 2 articles (01/2019 - 06/2015)
2.	Walsh, Gerald M: 2 articles (01/2019 - 06/2015)
3.	Agulnik, Mark: 1 article (01/2019)
4.	Frank, Nicole E: 1 article (01/2019)
5.	Klausner, Arthur: 1 article (01/2019)
6.	Milhem, Mohammed M: 1 article (01/2019)
7.	Talley, Todd T: 1 article (01/2019)
8.	Van Tine, Brian A: 1 article (01/2019)
9.	Bigelow, James C: 1 article (06/2015)
10.	Hohl, Raymond J: 1 article (06/2015)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2015 - "A phase I study was performed in order to determine the maximum-tolerated dose (MTD) of GPX-150 in patients with metastatic solid tumors. " 06/01/2015 - "Further investigation is needed to determine the efficacy of GPX-150 in anthracycline-sensitive malignancies." 06/01/2015 - "Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors."
2.	Cardiotoxicity 01/01/2019 - "In a preclinical chronic models and a phase I clinical study of GPX-150, no irreversible, cumulative dose-dependent cardiotoxicity was demonstrated. " 06/01/2015 - "GPX-150 administered every 21 days has an acceptable side effect profile and no cardiotoxicity was observed. "
3.	Sarcoma (Soft Tissue Sarcoma) 01/01/2019 - "An open-label, single-arm phase II clinical study in metastatic and unresectable soft tissue sarcoma (STS) patients was initiated to further evaluate the efficacy and safety of GPX-150, including cardiac function, specifically left ventricular ejection fraction (LVEF). "

Related Drugs and Biologics

1.	Anthracyclines